Johnson & Johnson (JNJ): FY25 Q1 earnings call, Apr 15, 2025
No Kalshi or Polymarket word markets were listed for Johnson & Johnson’s Apr 15, 2025 earnings call (FY25 Q1). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
6 matches for “Administration”; 4 quoted, at least 25 words apart.
…cancer. This was an important milestone for patients as subcutaneous riboflavin reduces administration time from hours to minutes. Our aspiration is for riboflavin plus LASCRUZ…
…Tremfya is currently the only IL-23 inhibitor with the flexibility of subcutaneous administration for both induction and maintenance dosing for the treatment of Crohn's disease,…
…I think it's also important that companies in healthcare partner with the administration to look to mitigate some of the vulnerabilities that exist today in…
…just to be clear that we want to be deferential to the administration and their process. That is speculative. Just looking at the pharmaceutical landscape…
Agents: this page as TSV at /api/v1/appearances/johnson-and-johnson:2025-04-15:earnings_call · words: /api/v1/brief?appearance=johnson-and-johnson:2025-04-15:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP